Tags

Type your tag names separated by a space and hit enter

Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
Eur J Obstet Gynecol Reprod Biol. 2005 Feb 01; 118(2):209-13.EJ

Abstract

OBJECTIVE

The aim of our study was to compare the effect of metformin applied independently to the effect of metformin used in combination with oral contraceptive containing ethinyl estradiol (EE) and cyproterone acetate (CA).

STUDY DESIGN

This prospective, open clinical study lasted 6 months and included 30 women with PCOS, divided in two groups of 15 women each. Group 1 received 850 mg metformin twice a day and group 2 in which Diane35 was added to the same treatment only during the first 2 months of the investigation. Serum levels of testosterone, immune reactive insulin (IRI), sex hormone binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS) and lipid metabolism parameters were measured before the treatment, on the third and sixth month. Free androgen index (FAI) and HOMA-IR were calculated. Body mass index (BMI) and waist-to-hip ratio (WHR) were assessed at baseline and at the end of therapy.

RESULTS

Much better and faster decrease in the level of testosterone and free androgen index in group with combined use of metformin and Diane35 was established, without deterioration of the anthropometric and biochemical indices and insulin sensitivity.

CONCLUSION

The combination of metformin with intermittent application of Diane35 is an appropriate alternative for the pathogenic influence and clinical improvement of the symptoms of androgen excess in cases with PCOS.

Authors+Show Affiliations

Mitkov M
Department of Endocrinology, Medical University, Plovdiv, Bulgaria.
Pehlivanov B
No affiliation info available
Terzieva D
No affiliation info available

MeSH

AdultAndrogen AntagonistsBody Mass IndexCyproterone AcetateDehydroepiandrosterone SulfateDrug CombinationsDrug Therapy, CombinationEthinyl EstradiolFemaleHumansHypoglycemic AgentsInsulinInsulin ResistanceMetforminPolycystic Ovary SyndromeProspective StudiesSex Hormone-Binding GlobulinTestosteroneWaist-Hip Ratio

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

15653205

Citation

Mitkov, M, et al. "Combined Use of Metformin and Ethinyl Estradiol-cyproterone Acetate in Polycystic Ovary Syndrome." European Journal of Obstetrics, Gynecology, and Reproductive Biology, vol. 118, no. 2, 2005, pp. 209-13.
Mitkov M, Pehlivanov B, Terzieva D. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2005;118(2):209-13.
Mitkov, M., Pehlivanov, B., & Terzieva, D. (2005). Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 118(2), 209-13.
Mitkov M, Pehlivanov B, Terzieva D. Combined Use of Metformin and Ethinyl Estradiol-cyproterone Acetate in Polycystic Ovary Syndrome. Eur J Obstet Gynecol Reprod Biol. 2005 Feb 1;118(2):209-13. PubMed PMID: 15653205.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. AU - Mitkov,M, AU - Pehlivanov,B, AU - Terzieva,D, PY - 2004/05/06/received PY - 2004/06/19/revised PY - 2004/06/30/accepted PY - 2005/1/18/pubmed PY - 2005/6/2/medline PY - 2005/1/18/entrez SP - 209 EP - 13 JF - European journal of obstetrics, gynecology, and reproductive biology JO - Eur J Obstet Gynecol Reprod Biol VL - 118 IS - 2 N2 - OBJECTIVE: The aim of our study was to compare the effect of metformin applied independently to the effect of metformin used in combination with oral contraceptive containing ethinyl estradiol (EE) and cyproterone acetate (CA). STUDY DESIGN: This prospective, open clinical study lasted 6 months and included 30 women with PCOS, divided in two groups of 15 women each. Group 1 received 850 mg metformin twice a day and group 2 in which Diane35 was added to the same treatment only during the first 2 months of the investigation. Serum levels of testosterone, immune reactive insulin (IRI), sex hormone binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS) and lipid metabolism parameters were measured before the treatment, on the third and sixth month. Free androgen index (FAI) and HOMA-IR were calculated. Body mass index (BMI) and waist-to-hip ratio (WHR) were assessed at baseline and at the end of therapy. RESULTS: Much better and faster decrease in the level of testosterone and free androgen index in group with combined use of metformin and Diane35 was established, without deterioration of the anthropometric and biochemical indices and insulin sensitivity. CONCLUSION: The combination of metformin with intermittent application of Diane35 is an appropriate alternative for the pathogenic influence and clinical improvement of the symptoms of androgen excess in cases with PCOS. SN - 0301-2115 UR - https://www.unboundmedicine.com/medline/citation/15653205/Combined_use_of_metformin_and_ethinyl_estradiol_cyproterone_acetate_in_polycystic_ovary_syndrome_ DB - PRIME DP - Unbound Medicine ER -